Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma Non-resectable

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Queen's Medical Center, Honolulu, Hawaii, United States
Contact: Study coordinator (Miles Sato, MS) · msato@queens.org · 808-691-8584
Contact: Study coordinator (Sandi A Kwee, MD) · skwee@queens.org · 808-691-5466
Contact: Principal Investigator (Sandi A Kwee, MD)

Study leads

Sandi A Kwee, MD, PhD
Principal Investigator
The Queen's Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Grenoble, France · Lille, France

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Taoyuan City, Taiwan

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Hepatocellular Carcinoma Non-Resectable

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Guangzhou, China